# Genprex, Inc. (GNPX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $138,182.545  
**Price:** $0.64 (-4.35%)

> Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The company's technologies deliver disease-fighting genes to address unmet needs in these patient populations. Its oncology program employs the systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to encapsulate gene-expressing plasmids targeting cancer cells. The lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with programs receiving FDA Fast Track and Orphan Drug designations. For diabetes, Genprex advances GPX-002, utilizing an AAV vector to deliver Pdx1 and MafA genes to the pancreas; in Type 1 diabetes, it transforms alpha cells into insulin-producing beta-like cells that evade immune detection, while in Type 2, it rejuvenates exhausted beta cells. Recent efforts include licensing additional technologies for glioblastoma treatment and advancing diabetes research with non-viral delivery systems. Founded in 2009 and headquartered in Austin, Texas, Genprex collaborates with leading institutions to expand its gene therapy pipeline in oncology and endocrinology.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | — | — | -$21M | -$21M | — |
| 2023 | — | — | -$31M | -$31M | — |
| 2022 | — | — | -$24M | -$24M | — |
| 2021 | — | — | -$21M | -$21M | — |
| 2020 | — | — | -$18M | -$18M | — |
| 2018 | — | — | -$12M | -$12M | — |
| 2017 | — | — | -$3M | -$3M | — |
| 2016 | — | — | -$4M | -$4M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $4M | $3M | $2M | $2M | — |
| 2023 | $11M | $3M | $7M | $7M | — |
| 2022 | $25M | $3M | $22M | $21M | — |
| 2021 | $43M | $2M | $41M | $39M | — |
| 2020 | $31M | $450,724 | $31M | $27M | — |
| 2018 | $9M | $387,821 | $9M | — | — |
| 2017 | $1M | $830,964 | $428,574 | $161,251 | — |
| 2016 | $2M | $285,661 | $2M | $2M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$15M | — | — |
| 2024 | -$18M | — | — |
| 2023 | -$25M | — | — |
| 2022 | -$18M | — | -$18M |
| 2021 | -$14M | $31,700 | -$14M |
| 2020 | -$14M | $17,564 | -$14M |
| 2019 | -$7M | $33,370 | -$7M |
| 2018 | -$7M | $22,435 | -$7M |
| 2017 | -$2M | $5,889 | -$2M |
| 2016 | -$1M | $4,978 | -$1M |

Source: [CompaniesByCap](https://companiesbycap.com/company/GNPX)